Are there related-party or family relationships linked to IMAX (IMAX) interim PEO role?

The company indicates there are no family relationships between Robert D. Lister and any IMAX directors or executive officers. It also notes there are no transactions requiring disclosure under Item 404(a) of Regulation S-K associated with his appointment as interim principal executive officer.

IMAX (NYSE: IMAX) taps legal chief as interim executive leader

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

IMAX Corporation temporarily adjusted its leadership structure while CEO Richard Gelfond is on medical leave. The board appointed Robert D. Lister, currently Chief Legal Officer and Senior Executive Vice President, to serve as interim principal executive officer until May 1, 2026, when Mr. Gelfond will resume the role.

Mr. Lister will keep his existing responsibilities and will not receive any additional compensation for this interim assignment. The company states there are no special arrangements, related-party transactions, new or amended contracts, or family relationships connected to his appointment, and incorporates his biography by reference from a prior proxy statement.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Interim appointment date: April 16, 2026 Expected end of interim role: May 1, 2026 Report signature date: April 17, 2026

3 metrics

Interim appointment date April 16, 2026 Board appointed Robert D. Lister as interim principal executive officer

Expected end of interim role May 1, 2026 Date when Richard Gelfond will resume principal executive officer role

Report signature date April 17, 2026 Date the 8-K was signed by IMAX officers

Key Terms

principal executive officer, definitive proxy statement, Schedule 14A, Item 404(a) of Regulation S-K, +1 more

5 terms

principal executive officer regulatory

"appointed Robert D. Lister ... to serve as the Company’s interim principal executive officer"

definitive proxy statement regulatory

"Biographical and other information for Mr. Lister are set forth in the Company’s definitive proxy statement"

A Definitive Proxy Statement is a detailed document that a company sends to its shareholders before a big meeting, like voting on important decisions. It explains what's being voted on and gives important information so shareholders can make informed choices. It matters because it helps shareholders understand and participate in key company decisions.

Schedule 14A regulatory

"definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission"

Schedule 14A is a document that companies file with regulators to share important information with shareholders before a big vote, like approving a merger or election of directors. It matters because it helps investors understand what’s happening so they can make informed decisions about the company’s future.

Item 404(a) of Regulation S-K regulatory

"not a party to any arrangement or understanding ... or to any transactions required to be disclosed pursuant to Item 404(a) of Regulation S-K"

emerging growth company regulatory

"Emerging growth company Item 5.02 Departure of Directors or Certain Officers"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Understanding 8-K Material Events →

04/17/2026 - 04:17 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

April 16, 2026

Date of report (Date of earliest event reported)

IMAX Corporation

(Exact Name of Registrant as Specified in Its Charter)

Canada

001-35066

98-0140269

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification Number)


2525 Speakman Drive			902 Broadway, Floor 20
Mississauga, Ontario, Canada L5K 1B1			New York, New York, USA 10010
(905) 403-6457			(212) 821-0142

(Address of principal executive offices, zip code, telephone numbers)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Shares, no par value

IMAX

The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter):

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As previously announced on March 30, 2026, Richard Gelfond, the Chief Executive Officer of IMAX Corporation (the “Company”), is on a temporary medical leave of absence. On April 16, 2026, the Company’s board of directors (the “Board”) appointed Robert D. Lister, the Company’s Chief Legal Officer and Senior Executive Vice President, to serve as the Company’s interim principal executive officer (“PEO”) in addition to his current duties until May 1, 2026, following which Mr. Gelfond will resume the role of PEO. Mr. Lister will not receive any additional compensation in connection with his temporary interim appointment.

Biographical and other information for Mr. Lister are set forth in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission (the “SEC”) on April 25, 2025 and are incorporated herein by reference. Mr. Lister is not a party to any arrangement or understanding pursuant to which he was appointed as interim PEO, or to any transactions required to be disclosed pursuant to Item 404(a) of Regulation S-K. The Company has not entered into, amended or modified any plan, contract, arrangement, grant or award in connection with the interim appointment of Mr. Lister. There are no family relationships between Mr. Lister and any of the Company’s other directors or executive officers.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	IMAX Corporation
	(Registrant)

Date: April 17, 2026	By:	/s/ Natasha Fernandes
	Name:	Natasha Fernandes
	Title:	Chief Financial Officer and Executive Vice President

	By:	/s/ Kenneth I. Weissman
	Name:	Kenneth I. Weissman
	Title:	Deputy General Counsel & Corporate Secretary

Source: View Original Filing on SEC EDGAR

FAQ

What leadership change did IMAX (IMAX) disclose in this 8-K?

IMAX temporarily named Chief Legal Officer Robert D. Lister as interim principal executive officer. He will serve in this role during CEO Richard Gelfond’s medical leave and is expected to hold it only until May 1, 2026, alongside his existing responsibilities.

How long will Robert D. Lister serve as interim PEO at IMAX (IMAX)?

Robert D. Lister is expected to serve as interim principal executive officer until May 1, 2026. After that date, the company states that CEO Richard Gelfond will resume the principal executive officer role, returning IMAX’s top leadership structure to its prior arrangement.

Will IMAX (IMAX) pay Robert D. Lister extra compensation as interim PEO?

IMAX reports that Robert D. Lister will not receive any additional compensation for serving as interim principal executive officer. He will continue in his existing roles while temporarily assuming the principal executive responsibilities during CEO Richard Gelfond’s medical leave.

Did IMAX (IMAX) enter any new contracts tied to the interim PEO appointment?

IMAX states it has not entered into, amended, or modified any plan, contract, arrangement, grant, or award in connection with Robert D. Lister’s interim principal executive officer role. The change is presented as a temporary assignment using the company’s existing governance framework.

Where can investors find biographical information on IMAX (IMAX) interim PEO Robert D. Lister?

IMAX refers investors to its definitive proxy statement on Schedule 14A filed with the SEC on April 25, 2025. That document contains biographical and other information about Robert D. Lister, which the company incorporates by reference into this current leadership change disclosure.

Filing Exhibits & Attachments

4 documents